Condition
Superficial Bladder Cancer clinical trials and research
Research outlook What's coming for Bladder cancer: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 2 Superficial Bladder Cancer clinical trials that are recruiting, at sites in 11 countries (most in Australia (1), Canada (1), France (1)). By phase: Phase 1/2 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 11Countries
All recruiting trials (2)
-
EG-70 treatment for patients with high-risk non-muscle invasive bladder cancer
This study is testing a new gene therapy called EG-70 to see if it can help patients with high-risk bladder cancer who haven't responded to or haven't received standard treatment.
-
Using metformin to treat non-muscle-invasive bladder cancer
This study tests if the diabetes drug metformin can help treat low-grade non-muscle-invasive bladder cancer in patients by seeing how well it works over three months.
Related topics
Quick answers
How many Superficial Bladder Cancer clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 11 countries. The most sites are in Australia (1 trial), Canada (1 trial), France (1 trial), Germany (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.